A Pure-Play FcRn Antibody Bet Trading Below Cash-Adjusted Fair Value

Viridian Therapeutics, Inc. (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on discovering and developing precision antibody therapies for patients with serious autoimmune and rare diseases. The company's core scientific focus is on validated but difficult-to-drug biological pathways, most notably the insulin-like growth factor 1 receptor (IGF-1R) and FcRn biology.

How it makes money: Viridian is pre-commercial and currently generates no product revenue. Its funding comes from equity capital markets activity, and its economic model is built around advancing pipeline assets through clinical development to either commercialization or partnership/acquisition. The company's value is therefore a function of pipeline NPV rather than current cash flows.

Lead program — VRDN-001: An anti-IGF-1R monoclonal antibody being developed for thyroid eye disease (TED), including both active and chronic manifestations. IGF-1R inhibition is a clinically validated mechanism following the approval of teprotumumab, and Viridian is positioning VRDN-001 on differentiation in dosing, tolerability, and efficacy.

Pipeline breadth: The company is advancing additional assets including VRDN-002 and earlier-stage programs, with the strategic intent of building a multi-indication immunology franchise rather than a single-product story.

Customers and scale: As a pre-revenue entity, Viridian's "customers" are ultimately patients, prescribers (endocrinologists and ophthalmologists), and payers. The company operates at a scale typical of a late-clinical-stage biotech: a focused R&D organization, a market cap of $2.4B, 113.29M shares outstanding, and a public float of 100.79M shares. Its EPS of -$3.40 reflects the substantial R&D investment required to fund Phase 3 development.

Near-term (12-24 months):

• Phase 3 clinical readouts for VRDN-001 in TED are the single most important near-term value driver. Positive data would de-risk the asset and likely catalyze a re-rating.
• Regulatory interactions — including pre-BLA meetings and potential submission — would mark the transition from clinical to commercial preparation and could attract partnership interest.
• Pipeline advancement for VRDN-002 and other programs provides incremental news flow and optionality.
• Financing events — given the -$3.40 EPS and clinical burn, additional capital raises are likely and will be a swing factor for share count and dilution.

Medium-term (2-5 years):

• Potential commercialization of VRDN-001 in TED, with revenue ramp dependent on label breadth, pricing, and payer coverage relative to Tepezza.
• Indication expansion into chronic TED and potentially other IGF-1R-mediated conditions, broadening the addressable market.
• FcRn and complement pipeline maturation, which could establish Viridian as a multi-franchise immunology player and support a higher terminal multiple.
• Strategic optionality — a validated, differentiated TED asset in a market with a large incumbent is a natural partnership or acquisition target for larger biopharma.

Note: Historical and projected figures beyond the confirmed current EPS of -$3.40 are indicative estimates reflecting the typical burn profile of a late-clinical-stage biotech and should be treated as directional, not precise.

What's driving the numbers: Viridian's financials are dominated by R&D spending on Phase 3 TED trials and pipeline advancement, with no offsetting revenue. The -$3.40 EPS reflects this cash burn. The key financial question is runway: the company must fund operations through its Phase 3 readouts and potential BLA submission, and any shortfall will require equity issuance. Because the company is pre-revenue, traditional margin analysis is not yet meaningful; instead, investors should focus on cash runway, burn rate, and the dilution implied by future raises. The path to positive EPS depends entirely on successful commercialization of VRDN-001, which would convert the current negative-earnings profile into a revenue-generating one.

Market size / TAM: The global thyroid eye disease market is estimated in the low single-digit billions of dollars annually and is expected to grow as diagnosis improves and treatment penetrates a historically under-served patient population. Broader autoimmune and rare-disease markets targeted by Viridian's pipeline represent a TAM well into the tens of billions, though Viridian's realistic addressable share is a fraction of that.

Competitive positioning: Viridian is a challenger in TED, entering behind an established incumbent but with a differentiated antibody design. Its success hinges on demonstrating a competitive efficacy/safety/dosing profile and securing payer access in a market where reimbursement has been a friction point.

Named comparable companies:

• Amgen (AMGN) — via Tepezza (teprotumumab), the incumbent and validating player in TED.
• Horizon Therapeutics / Amgen — historical TED commercial execution benchmark.
• Immunovant (IMVT) — a fellow FcRn/autoimmune-focused clinical-stage biotech and close valuation comparable.
• argenx (ARGX) — a commercial-stage immunology company often used as a premium-multiple benchmark for successful autoimmune franchises.

Viridian's relative positioning is that of a clinical-stage challenger with pipeline optionality — higher risk than commercial-stage peers like argenx, but with potentially greater upside if its TED asset differentiates successfully.

DCF discussion: A discounted cash flow analysis for Viridian is highly sensitive to assumptions about VRDN-001's probability of success, peak penetration, pricing, and the timing of commercialization. Because the company is pre-revenue and dependent on binary clinical outcomes, a probability-weighted DCF is more appropriate than a single-scenario model. Under a base case assuming a successful Phase 3, a mid-teens share of the TED market, and a 10-12% discount rate, the risk-adjusted NPV supports a valuation in the low-to-mid $20s per share. A bull case incorporating pipeline expansion and a higher peak-share assumption supports the high $20s to low $30s, while a bear case (clinical miss or weak differentiation) points toward the low teens, consistent with the 52-week low of $13.18.

Comparable-company multiples:

Because Viridian has no revenue, EV/sales and P/E multiples are not applicable. Instead, the market values the company on pipeline NPV relative to peers. At a $2.4B market cap, Viridian trades at a discount to commercial-stage immunology peers (argenx, Amgen) but at a premium to some earlier-stage peers — reflecting the late-stage nature of its lead asset and the associated binary risk.

• Clinical/regulatory risk: VRDN-001 may fail to meet primary endpoints in Phase 3 or face regulatory setbacks, which would be catastrophic for a company whose value is concentrated in this asset.
• Competitive risk: Amgen's Tepezza is the entrenched incumbent with established physician relationships, payer contracts, and real-world data. Viridian must overcome incumbent advantage and may face pricing pressure.
• Financing/dilution risk: With a -$3.40 EPS and no revenue, Viridian will likely need to raise additional capital, diluting existing shareholders, potentially at unfavorable prices given the depressed share price.
• Reimbursement/payer risk: TED therapies have faced payer friction; even a superior product could struggle with coverage and patient access, limiting commercial uptake.
• High short interest / volatility risk: With 17.85% of float shorted, the stock is prone to violent moves in both directions around catalysts, increasing volatility and the risk of adverse positioning dynamics.